Marc Tessier-Lavigne - Jun 2, 2022 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Jun 2, 2022
Transactions value $
$0
Form type
4
Date filed
6/6/2022, 08:09 PM
Previous filing
Jun 28, 2022
Next filing
Jun 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Award $0 +5.99K +0.3% $0.00 2.03M Jun 2, 2022 Direct F1, F2
holding DNLI Common Stock 78.8K Jun 2, 2022 The Tessier-Lavigne/Hynes Irrevocable Trust 1
holding DNLI Common Stock 79.2K Jun 2, 2022 The Tessier-Lavigne/Hynes Irrevocable Trust 2
holding DNLI Common Stock 78.8K Jun 2, 2022 The Tessier-Lavigne/Hynes Irrevocable Trust 3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Award $0 +18K $0.00 18K Jun 2, 2022 Common Stock 18K $24.27 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2 Includes 5,986 unvested restricted stock units.
F3 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.